[CCMC 13421-R] CCMC Canadian code compliance evaluation
From: National Research Council Canada
BASF Canada Inc. o/a BASF Canada
100 Milverton, 5th Floor
In most jurisdictions this document is sufficient evidence for approval by Canadian authorities.Learn more about CCMC recognition Look for the trusted CCMC mark on products to verify compliance.
It is the opinion of the Canadian Construction Materials Centre that the evaluated products, when used as binders for oriented strandboard (OSB) and waferboard in accordance with the conditions and limitations stated in this evaluation, comply with the following code:
National Building Code of Canada 2015
|ID||Code provision||Solution type|
|09-23-15-02-00-0-00||22.214.171.124. Material Standards||Alternative|
|09-23-16-02-00-0-00||126.96.36.199. Material Standards||Alternative|
|09-23-17-02-00-0-00||188.8.131.52. Thickness, Rating and Material Standards||Alternative|
|09-27-10-01-00-0-00||184.108.40.206. Material Standard||Alternative|
|09-29-09-01-00-0-00||220.127.116.11. Material Standard||Alternative|
|09-30-02-02-00-0-00||18.104.22.168. Materials and Thickness||Alternative|
The above opinion(s) is/are based on the evaluation by the CCMC of technical evidence provided by the evaluation holder, and is bound by the stated conditions and limitations. For the benefit of the user, a summary of the technical information that forms the basis of this evaluation has been included.
- Lupranate M20
- Lupranate M20FB
Product descriptionThe products are polymeric methylene diphenyl diisocyanate (MDI) binders used for the manufacturing of OSB and waferboard.
This evaluation is valid only for products produced at the following plant:
|Product names||Manufacturing plant|
|Geismar, LA, US|
|Lupranate M20||Product evaluated by the CCMC|
|Lupranate M20FB||Product evaluated by the CCMC|
Product evaluated by the CCMC Indicates that the product from this manufacturing facility has been evaluated by the CCMC
Conditions and limitations
The CCMC’s compliance opinion is bound by this product being used in accordance with the conditions and limitations set out below.
- The products may be used for the bonding of strands in the manufacturing of OSB products that are intended to conform to the requirements of CSA O437.2-93 as referenced in CSA O325-07, Article 5.2.3A. Each finished product (i.e., OSB panel) using Lupranate M20 and Lupranate M20FB must conform to CSA O325-07.
This evaluation is based on demonstrated conformance with the following criteria:
|Criteria number||Criteria name|
|CCMC-TG-060523.08-15||CCMC Technical Guide for Binders for Oriented Strandboard (OSB) and Waferboard|
The evaluation holder has submitted technical documentation for the CCMC evaluation. Testing was conducted at laboratories recognized by the CCMC. The corresponding technical evidence for this product is summarized below.
|Modulus of rupture (MOR) after preconditioning||MPa||≥ 17.2 average||42.6 average|
|MPa||≥ 13.8 individual||34.2 individual|
|Modulus of elasticity (MOE) after preconditioning||MPa||≥ 3 100 average||5 226 average|
|MPa||≥ 2 480 individual||4 027 individual|
|Internal bond after preconditioning||MPa||≥ 0.345 average||0.935 average|
|MPa||≥ 0.276 individual||0.838 individual|
|Bond durability: MOR after 2-h boil (tested when wet)||MPa||≥ 8.6 average||22.4 average|
|MPa||≥ 6.9 individual||18.0 individual|
|Bond durability: MOR after six cycles||MPa||≥ 8.6 average||32.0 average|
|MPa||≥ 6.9 individual||23.9 individual|
|Thickness swell: 24-h soak||%||≤ 25 average||3.8 average|
|%||≤ 30 individual||4.4 individual|
|Linear expansion: oven-dry to saturated||%||≤ 0.40 average||0.26 average|
|%||≤ 0.48 individual||0.30 individual|
|Linear expansion: 50% to 90% relative humidity (RH)||%||≤ 0.20 average||0.10 average|
|%||≤ 0.24 individual||0.11 individual|
|Cumulative creep||mm||≤ 1.7 average||1.0 average|
|≤ 2.04 individual||1.14 individual|
|Secondary creep||mm||≤ 0.4 average||0.2 average|
|≤ 0.48 individual||0.28 individual|
|Irrecoverable creep||mm||≤ 1.1 average||0.6 average|
|≤ 1.32 individual||0.66 individual|
|Cumulative creep||mm||≤ 2.2 average||0.9 average|
|≤ 2.64 individual||1.09 individual|
|Secondary creep||mm||≤ 0.4 average||0.1 average|
|≤ 0.48 individual||0.15 individual|
|Irrecoverable creep||mm||≤ 1.5 average||0.5 average|
|≤ 1.8 individual||0.66 individual|
|Cumulative creep||%||≤ 35 average||−9 average|
|≤ 42 individual||−5 individual|
|Secondary creep||%||≤ 0 average||−46 average|
|≤ 0 individual||−41 individual|
|Irrecoverable creep||%||≤ 50 average||−9 average|
|≤ 60 individual||0 individual|
|Exposure after 2-h boil (modified)||MPa||≥ 8.6 average||40.1 average|
|≥ 6.9 individual||30.2 individual|
|Exposure after six-cycle test||MPa||≥ 8.6 average||32.0 average|
|≥ 6.9 individual||23.9 individual|
|At −20°C||MPa||≥ 17.2 average||49.8 average|
|≥ 13.8 individual||36.9 individual|
|After fungal exposure: Aspergillus niger vs. Teigh||MPa||≥ 13.8 average||46.2 average|
|≥ 11.0 individual||36.1 individual|
|After fungal exposure: Penicillium luteum||MPa||≥ 13.8 average||42.7 average|
|≥ 11.0 individual||30.0 individual|
|After soaking in 1% hydrochloric acid||MPa||≥ 7.7 average||26.2 average|
|≥ 6.2 individual||17.8 individual|
|After soaking in 1% sodium hydroxide||MPa||≥ 12.0 average||29.9 average|
|≥ 9.6 individual||25.8 individual|
|After soaking in water||MPa||≥ 14.6 average||34.9 average|
|≥ 11.7 individual||24.6 individual|
|Exposure after 2-h boil (modified)||MPa||≥ 1 550 average||5 123 average|
|≥ 1 240 individual||4 275 individual|
|Exposure after six-cycle test||MPa||≥ 2 015 average||4 523 average|
|≥ 1 612 individual||4 027 individual|
|At −20°C||MPa||≥ 3 100 average||5 771 average|
|≥ 2 480 individual||4 950 individual|
|After fungal exposure: Aspergillus niger vs. Teigh||MPa||≥ 2 480 average||5 295 average|
|≥ 1 984 individual||4 447 individual|
|After fungal exposure: Penicillium luteum||MPa||≥ 2 480 average||5 109 average|
|≥ 1 984 individual||4 585 individual|
|After soaking in 1% hydrochloric acid||MPa||≥ 2 480 average||4 606 average|
|≥ 1 984 individual||3 923 individual|
|After soaking in 1% sodium hydroxide||MPa||≥ 2 325 average||4 171 average|
|≥ 1 860 individual||3 723 individual|
|After soaking in water||MPa||≥ 2 790 average||4 771 average|
|≥ 2 232 individual||4 268 individual|
Retention properties - internal bond
There is no individual result for the internal bond property given that the residual property requirements apply to the average of three test specimens for each test board.
|Exposure after 2-h boil (modified)||MPa||≥ 0.104||0.575|
|Exposure after six-cycle test||MPa||≥ 0.035||0.389|
|At −20°C||MPa||≥ 0.345||1.038|
|After fungal exposure: Aspergillus niger vs. Teigh||MPa||≥ 0.207||0.760|
|After fungal exposure: Penicillium luteum||MPa||≥ 0.207||0.745|
|After soaking in 1% hydrochloric acid||MPa||≥ 0.069||0.527|
|After soaking in 1% sodium hydroxide||MPa||≥ 0.155||0.591|
|After soaking in water||MPa||≥ 0.224||0.674|
Use of Canadian Construction Materials Centre (CCMC) assessments
This assessment must be read in the context of the entire CCMC Registry of Product Assessments, any applicable building code or by-law requirements, and/or any other regulatory requirements (for example, the Canada Consumer Product Safety Act, the Canadian Environmental Protection Act, etc.).
It is the responsibility of the user to confirm that the assessment they are using is current and has not been withdrawn or superseded by a later version on the CCMC Registry of Product Assessments.
The National Research Council of Canada (NRC) has evaluated only the characteristics of the specific product described herein. The information and opinions in this evaluation are directed to those who have the appropriate degree of experience to use and apply its contents (such as authorities having jurisdiction, design professionals and specifiers). This evaluation is valid when the product is used as part of permitted construction, respecting all conditions and limitations stated in the evaluation, and in accordance with applicable building codes and by-laws.
This evaluation is provided without representation, warranty or guarantee of any kind, expressed or implied, and the NRC provides no endorsement for any evaluated product. The NRC accepts no responsibility whatsoever arising in any way from any and all use of or reliance on the information contained herein or the use of any evaluated product. The NRC is not undertaking to render professional or other services on behalf of any person or entity nor to perform any duty owed by any person or entity to another person or entity.
Une version française de ce document est disponible.
In the case of any discrepancy between the English and French version of this document, the English version shall prevail.
© His Majesty the King in Right of Canada, as represented by the National Research Council of Canada, 2023
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the CCMC.